To read the full story, subscribe or sign in.

Bridgebio seeks Japan approval of acoramidis for rare heart disease

Feb. 5, 2024

Armed with strong phase III safety data in Japanese patients, Palo Alto, Calif.-based Bridgebio Pharma Inc. is planning to file for Japan approval of its investigational drug acoramidis for a rare heart disorder.

BioWorld Cardiovascular Asia-Pacific Japan MHLW

Today's news in brief

BioWorld

BioWorld briefs for July 21, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 21, 2025.

Coinfections and diversity paint the many shades of HIV cure

BioWorld

We all look different to HIV, a virus that destroys the immune system. The defensive cells record every interaction with foreign agents, infections from viruses...

Livzon’s IL-17A/F meets phase III endpoints in plaque psoriasis

BioWorld

Livzon Mabpharm Inc.’s anti-IL-17A/F monoclonal antibody, LZM-012, met the primary endpoint in a phase III trial in moderate to severe plaque psoriasis. Conducted...

Sino to acquire Lanova and pipeline for up to $950M

BioWorld Asia

Sino Biopharmaceutical Ltd. agreed to fully acquire Lanova Medicines Ltd. by buying an additional 95.09% stake in Lanova at a valuation of up to $950.92 million....